8 completed, 2 recruiting, 2 terminated, 2 unknown. 7 Phase 4, 3 Not applicable, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Not applicable | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow lercanidipine: new trials by email Literature Review of lercanidipine trials Research Report on lercanidipine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Role of Skin Sodium Accumulation in Chronic Kidney Disease Hydrochlorothiazide, Spironolactone, Lercanidipine - Chronic Kidney Diseases | Not applicable | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 60 | 2025-01-07 | 2025-06-13 |
| Bariatric Surgery and Pharmacokinetics of Lercanidipine Lercanidipine - Obesity, Morbid | Recruiting | Norwegian University of Science and Technology | 12 | 2016-11-02 | 2026-07-08 | |
| Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) Lisinopril, Amlodipine - Renal Insufficiency, Chronic, Proteinuria | Phase 4 | Unknown | Hospital General Universitario Gregorio Marañon | 106 | 2015-06-01 | 2019-02-22 |
| Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Lercanidipine 10mg, Lercanidipine10mg /Valsartan 80mg, Lercanidipine 10mg /Valsartan 160mg - Hypertension | Phase 3 | Completed | LG Life Sciences | 449 | 2012-05-01 | 2013-08-28 |
| Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension Zanidip, Felodipine sustained-release tablet - Hypertension | Phase 4 | Completed | Lee's Pharmaceutical Limited | 281 | 2011-12-01 | 2014-10-16 |
| Zainidip in Renal Artery Stenosis stent, Aspirine, Clopidogrel - Hypertension | Phase 4 | Completed | Lee's Pharmaceutical Limited | 149 | 2011-09-01 | 2015-11-03 |
| Antihypertensive Efficacy of Fixed Combination Drug Lercanidipine/enalapril fixed combination - Hypertension | Phase 4 | Terminated | Meir Medical Center | 10 | 2011-01-01 | 2016-06-28 |
| Intensive Vasodilator Therapy in Patients With Essential Hypertension Amlodipine, Ramipril, Lercanidipine - Essential Hypertension, High Blood Pressure | Phase 4 | Completed | Aarhus University Hospital | 48 | 2010-12-01 | 2012-04-19 |
| Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension Placebo, Lercanidipine, Enalapril - Essential Hypertension | Phase 2 | Completed | RECORDATI GROUP | 1039 | 2010-03-01 | 2011-04-29 |
| Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension Lercanidipine + Valsartan, Lercanidipine or Valsartan, Placebo - Essential Hypertension | Phase 2 | Completed | LG Life Sciences | 441 | 2009-12-01 | 2011-02-18 |
| Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Any antihypertensive medication alone or in combination, Ambulatory blood pressure monitoring - Essential Hypertension, Cardiovascular Disease | Phase 4 | Completed | University of Vigo | 21983 | 2008-09-01 | 2018-08-28 |
| Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine candesartan, lercanidipine - HIV Infections, Hypertension | Phase 4 | Unknown | Università degli Studi dell'Insubria | 30 | 2007-09-01 | 2007-12-06 |
| Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris Lercanidipine, Valsartan, Nicorandil - Microvascular Angina, Hypertension | Not applicable | Terminated | University of Aarhus | 10 | 2007-01-01 | 2009-05-06 |
| Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients Lercanidipine - Hypertension | Not applicable | Completed | UCB Pharma | 180 | 2004-05-01 | 2008-03-10 |
Hypertension (10) · Essential Hypertension (4) · Renal Insufficiency, Chronic (3) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 2 (1) · HIV Infections (1) · Microvascular Angina (1) · Obesity (1) · Obesity, Morbid (1) · Proteinuria (1) · Stroke (1)
LG Life Sciences (2) · Lee's Pharmaceutical Limited (2) · Aarhus University Hospital (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Hospital General Universitario Gregorio Marañon (1) · Meir Medical Center (1) · Norwegian University of Science and Technology (1) · RECORDATI GROUP (1) · UCB Pharma (1) · University of Aarhus (1) · University of Vigo (1) · Università degli Studi dell'Insubria (1)
China (2) · Denmark (2) · South Korea (2) · Spain (2) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Norway (1)
Ashkan Eftekhari, MD, PhD (1) · Eduardo Podjarny, MD (1) · Giuseppe Mancia, Prof (1) · Kent L Christensen, MD, DrMSc (1) · Maria Angeles Goicoechea, PhD, MD (1) · Morten Engholm Pedersen, MD (1) · Niels Henrik Buus, DMSc (1) · Ole Norling Mathiasen, MD, PhD (1) · Ramon C Hermida, PhD (1) · Rik Olde Engberink, MD, PhD (1) · Won Yong Kim, MD, DrMSc (1)
PMID 26164786, PMID 26630216, PMID 27221952, PMID 27779454, PMID 31641769, PMID 38508877